We recently demonstrated that caveolae, vesicular flask-shaped invaginations of the plasma membrane represent novel therapeutic targets in multiple myeloma (MM). In the present study, we demonstrate that vascular endothelial growth factor (VEGF) triggers Src-dependent phosphorylation of caveolin-1, which is required for p130Cas phosphorylation and MM cell migration. Conversely, depletion of caveolin-1 by antisense methodology abrogates p130Cas phosphorylation and VEGF-triggered MM cell migration. The proteasome inhibitor bortezomib, both inhibited VEGF-triggered caveolin-1 phosphorylation and markedly decreased caveolin-1 expression. Consequently, bortezomib inhibited VEGF- induced MM cell migration. Bortezomib also decreased VEGF secretion in the bone marrow microenvironment and inhibited VEGF-triggered tyrosine phosphorylation of caveolin-1, migration, and survival in HUVECs.

Taken together, these studies demonstrate the requirement of caveolae for VEGF-triggered MM cell migration and identify caveolin-1 in MM cells and HUVECs as a molecular target of bortezomib.

Topics:
bortezomib, caveolins, cell motility, multiple myeloma, vascular endothelial growth factor a, molecular target, proteasome inhibitors, tyrosine, caveolae, bodily secretions

Author notes

Corresponding author

2005, The American Society of Hematology
2004
Sign in via your Institution